BG Medicine (OTCMKTS:BGMD) versus BioNexus Gene Lab (NASDAQ:BGLC) Critical Survey

BG Medicine (OTCMKTS:BGMD) and BioNexus Gene Lab (NASDAQ:BGLC) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Institutional & Insider Ownership

18.9% of BioNexus Gene Lab shares are owned by institutional investors. 6.5% of BG Medicine shares are owned by company insiders. Comparatively, 0.1% of BioNexus Gene Lab shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and target prices for BG Medicine and BioNexus Gene Lab, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BG Medicine	0	0	0	0	0.00
BioNexus Gene Lab	1	0	0	0	1.00

Given BG Medicine’s higher possible upside, equities analysts plainly believe BG Medicine is more favorable than BioNexus Gene Lab.

Profitability

This table compares BG Medicine and BioNexus Gene Lab’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BG Medicine	N/A	N/A	N/A
BioNexus Gene Lab	-54.70%	-37.43%	-32.88%

Volatility and Risk

BG Medicine has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, BioNexus Gene Lab has a beta of 4.09, suggesting that its share price is 309% more volatile than the S&P 500.

Valuation & Earnings

This table compares BG Medicine and BioNexus Gene Lab”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BG Medicine	N/A	N/A	N/A	N/A	N/A
BioNexus Gene Lab	$5.31 million	1.01	-$2.98 million	($1.48)	-1.50

BG Medicine has higher earnings, but lower revenue than BioNexus Gene Lab.

Summary

BG Medicine beats BioNexus Gene Lab on 5 of the 9 factors compared between the two stocks.

About BG Medicine

BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.

About BioNexus Gene Lab

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.